STOCK TITAN

Cingulate Inc - CINGW STOCK NEWS

Welcome to our dedicated news page for Cingulate (Ticker: CINGW), a resource for investors and traders seeking the latest updates and insights on Cingulate.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cingulate's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cingulate's position in the market.

Rhea-AI Summary
Cingulate Inc. appoints three new directors to its board following successful capital raising activities, including a recent public offering and sales under its ATM facility. The company raised $7.5 million in February 2024, $3.2 million through the ATM facility in January 2024, and converted $3.3 million of debt into equity. The new directors bring expertise in business, public markets, finance, healthcare, and pharmaceuticals to support the company's clinical trials and business growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.46%
Tags
management
-
Rhea-AI Summary
Biopharmaceutical company Cingulate Inc. (NASDAQ: CING) closed a public offering, raising $7.5 million in gross proceeds. The offering included 3,750,000 shares of common stock, Series A warrants, and Series B warrants. The company plans to utilize the net proceeds for research and development, commercialization activities, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.5%
Tags
offering
-
Rhea-AI Summary
Cingulate Inc. (CING) announced the pricing of its public offering of 3,750,000 shares of its common stock, Series A warrants for up to 3,750,000 shares, and Series B warrants for up to 1,875,000 shares at a public offering price of $2.00 per share. The offering is expected to raise significant capital for the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-60.42%
Tags
offering
Rhea-AI Summary
Cingulate Inc. (NASDAQ: CING) has promoted Controller Jennifer Callahan to Chief Financial Officer, succeeding longtime CFO Lou Van Horn. The company aims to strengthen its balance sheet through traditional and non-dilutive transactions, with Callahan expressing excitement to lead the finance team into the future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.59%
Tags
none
-
Rhea-AI Summary
Cingulate Inc. announced the conversion of $3.3 million of debt and accrued interest into equity by Werth Family Investment Associates, LLC, at a conversion price of $4.785 per share. The closing price of Cingulate’s common stock on Nasdaq on January 24, 2024, was $4.35 per share. WFIA also agreed to convert the remaining $3.0 million of principal under its outstanding note into pre-funded warrants to purchase 687,043 shares of Cingulate’s common stock. The offer and sale of the securities are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.59%
Tags
none
-
Rhea-AI Summary
Cingulate Inc. (NASDAQ: CING) has received guidance from the FDA to advance its investigational asset CTx-2103 for the treatment of anxiety into clinical development. The company plans to file an IND application in the first half of 2024 and design clinical studies for CTx-2103. This step may allow CTx-2103 to seek approval under the 505(b)(2) pathway, which typically requires less time and resources than the 505(b)(1) full NDA pathway. CTx-2103 is a once-daily, multi-dose tablet that provides three precisely timed doses of buspirone versus one immediate release dose, offering clear differentiation and compelling advantages over currently available treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
none
Rhea-AI Summary
Cingulate Inc. (NASDAQ: CING) announced financial results for Q3 2023, including Phase 3 adult efficacy and safety trial data for CTx-1301, a $4M public offering, and $5.8M of debt converted into CING equity. The clinical update highlighted the positive results from the Phase 3 trial, with significant improvements in ADHD patients. The company also provided insights into its R&D expenses and net loss figures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
earnings
-
Rhea-AI Summary
Cingulate Inc. will be hosting a key opinion leader event on October 23, 2023, focused on their late-stage asset CTx-1301 in ADHD and anxiety-related disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
conferences
-
Rhea-AI Summary
Cingulate Inc. closes public offering, raising approximately $4.0 million for research and development and commercialization activities of its lead candidate CTx-1301.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.32%
Tags
offering
Rhea-AI Summary
Cingulate Inc. announces pricing of public offering, expecting gross proceeds of approximately $4.0 million. The funds will be used for research and development, commercialization activities, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
offering
Cingulate Inc

Nasdaq:CINGW

CINGW Rankings

CINGW Stock Data

910.52k
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Kansas City